PDT: FDA Filing Boosts Ameluz® for Skin Cancer Treatment!

Company Overview: Biofrontera Inc. (NASDAQ: BFRI) is a U.S.-based biopharmaceutical company focused on dermatology, notably photodynamic therapy (PDT) for skin lesions. Its flagship drug Ameluz® (aminolevulinic acid gel) is approved for treating actinic keratosis (a pre-cancerous skin lesion) with a companion red-light lamp (RhodoLED). In February 2026, Biofrontera announced FDA acceptance of a supplemental New Drug Application (SNDA) to expand Ameluz-PDT’s label to include superficial basal cell carcinoma (SBCC) (www.globenewswire.com). This marks a key milestone – if approved by the September 28, 2026 PDUFA date, Ameluz® would become the first and only PDT drug indicated for basal cell carcinoma in the U.S., addressing the most common skin cancer (3.6 million cases annually) (www.globenewswire.com). Below, we examine Biofrontera’s dividend policy, financial leverage, valuation, and the major risks and questions facing the company in light of this development.

Dividend Policy & Yield

Biofrontera does not pay any dividends, nor has it historically. As an emerging biotech, all cash is reinvested into growth and R&D. The company explicitly states it has never paid dividends and has no plans to do so “for the foreseeable future” (www.sec.gov). Consequently, dividend yield is 0%, and metrics like FFO/AFFO are not applicable in this context (Biofrontera is not a REIT or income-producing asset). Investors in BFRI are thus relying on capital appreciation rather than income. This policy makes sense given Biofrontera’s ongoing clinical development expenses and need to achieve profitability before considering shareholder distributions.

Leverage, Debt, and Coverage

Biofrontera carries minimal debt after a recent balance sheet restructuring. The company had incurred a short-term high-interest loan, but paid off this expensive debt in 2024, substantially reducing interest expense (www.biospace.com). As of early 2025, Biofrontera reported essentially no long-term debt on its books and thus faces no significant near-term debt maturities. Instead of debt financing, Biofrontera funded its growth through equity: in mid-2025 it raised $11 million of new capital via a private placement of Series C convertible preferred stock (www.sec.gov). This financing was a condition to acquiring full U.S. rights to Ameluz from its German parent company. The second tranche of this raise closed in October 2025, bringing in the final $2.5 million of the $11 million round (www.globenewswire.com). Proceeds were used to purchase all U.S. assets and rights to Ameluz® and its lamps from Biofrontera AG, a transformative deal that closed in 4Q 2025 (www.globenewswire.com). As part of that deal, Biofrontera’s ongoing payment to the parent shifted from a hefty transfer price to a much lower royalty: it will now pay 12% of U.S. Ameluz sales (15% on sales above $65 million) as royalty, replacing the prior 25–35% of net sales cost structure (www.sec.gov). This dramatically improves future gross margins and frees up cash flow.

Despite the equity infusion, liquidity remains a concern. Biofrontera’s cash balance was only $3.4 million as of September 30, 2025 (www.globenewswire.com). Management did bolster cash in Q4 2025: the company received the $2.5 million final tranche from investors in October and also divested its Xepi® antibiotic cream for $3 million upfront (plus up to $7 million in milestones) (www.globenewswire.com). These moves provided non-dilutive cash, but overall liquidity is still tight relative to ongoing needs. With quarterly operating losses still in the millions, additional capital may be required in the future (see Risks below).

On a positive note, with debt repaid and the royalty model in place, interest expense is negligible and coverage ratios have improved. There are no significant interest payments to cover now. However, Biofrontera’s operations are not yet self-funding – core earnings remain negative. In Q3 2025, for example, Adjusted EBITDA was –$6.0 million (a deeper loss than –$4.6 million a year prior) (www.globenewswire.com). This underscores that the company still relies on external financing to cover its operating and R&D costs. In summary, Biofrontera has de-levered financially (no large debt overhang or near-term maturities), but its ability to cover fixed costs hinges on expanding revenue and controlling expenses until it reaches breakeven.

Valuation and Share Structure

Biofrontera’s stock market valuation appears modest relative to its revenues, reflecting investor skepticism about its profitability trajectory. At a share price around $0.75, Biofrontera’s market capitalization is only on the order of $9–12 million (www.macrotrends.net). For context, the company’s annual revenues in 2024–2025 are about $35–40 million, so the stock trades at roughly 0.3× sales – a steep discount to typical biotech or pharmaceutical multiples. This low valuation likely prices in the company’s continued losses and need for cash; investors are waiting for clear signs of sustainable profitability or successful expansion of Ameluz’s market before awarding a higher multiple.

It’s worth noting that Biofrontera’s capital structure is highly dilutive. As of December 2025 there were ~11.6 million common shares outstanding (www.sec.gov), but this number will rise as various preferred stock and warrants convert. The Series C preferred issued in 2025 (to raise the $11 million) is convertible into an estimated ~13 million new shares (initial tranche) plus 4 million from the second tranche (www.sec.gov) (www.sec.gov). Additionally, an older Series B preferred (from prior financings) could convert into over 12 million shares (www.sec.gov). Biofrontera’s German parent was issued Series D convertible preferred as part of the Ameluz rights buyout, which equates to roughly 4.8 million shares at full conversion (www.sec.gov). Finally, there are outstanding warrants from past PIPE offerings. In total, the fully diluted share count could more than double or triple the current outstanding shares over time. This overhang may be weighing on the stock’s valuation – investors anticipate that as the company’s prospects improve, conversions and exercises will increase the share count (diluting existing shareholders). In short, BFRI’s enterprise value is only modestly higher than its market cap, and the stock’s P/S ratio ~0.3 reflects both the company’s small scale and the dilution/capital risk embedded in the equity.

Risks and Red Flags

Biofrontera faces several significant risks and red flags that investors should monitor:

- Ongoing Losses & Dilution Risk: The company continues to operate at a net loss (≈$16 million net loss for the first 9 months of 2025) and will likely require additional financing to fund operations and new trials (www.globenewswire.com). Future equity raises or conversions of preferred stock would dilute current shareholders. This cycle of funding is a common risk for micro-cap biotechs and is reflected in Biofrontera’s low valuation.

- Nasdaq Compliance and Listing Risk: Biofrontera’s stock price has traded below $1 for extended periods, and its shareholders’ equity was recently negative. In May 2025, Nasdaq notified the company that it failed to meet continued listing standards (for stock price and equity levels) (www.sec.gov). By November 2025, Biofrontera faced potential delisting if it did not restore compliance with Nasdaq’s $2.5 million minimum equity rule (www.sec.gov). The recent capital raise and asset sale were partly aimed at curing this, but the company remains at risk of a Nasdaq delisting or a forced reverse stock split if the share price and equity position don’t improve. Removal from Nasdaq could severely impact liquidity and access to capital.

- Reliance on a Single Product: Ameluz® (and its PDT lamp) accounts for essentially all of Biofrontera’s revenue (www.globenewswire.com) after the sale of Xepi. This concentration means the company’s fortunes hinge on one product’s commercial success. Any setback – such as a new competing therapy, loss of exclusivity, or safety issue – could significantly hurt sales. Biofrontera explicitly acknowledges its “reliance on sales of [its] products as [its] sole source of revenue,” and the need for Ameluz to succeed in the market (www.globenewswire.com).

- Competitive and Market Adoption Risks: In the dermatology market, Biofrontera must compete with established treatments for actinic keratosis and basal cell carcinoma. For AK, dermatologists often use cryotherapy or other topical drugs; for sBCC, surgical excision is the standard of care. Convincing practitioners to adopt Ameluz-PDT in place of or alongside these standards is an ongoing challenge. Competitors (including Sun Pharma’s PDT drug Levulan and new topical therapies) also vie for market share (www.globenewswire.com). There is a risk that even with new FDA-approved indications, market adoption could be gradual. Additionally, reimbursement by insurance for PDT procedures is crucial – changes in provider reimbursement practices could impact utilization (www.globenewswire.com). Biofrontera will need to educate physicians and payers to drive uptake in new indications.

- Regulatory and Execution Risks: The sNDA for Ameluz in sBCC must still be reviewed by the FDA. While filing acceptance is positive, there is no guarantee of approval by the PDUFA date. Unexpected requests for more data or safety concerns could delay or derail approval. Moreover, Biofrontera is running trials for other uses (like Ameluz in acne and on body areas for AK); each of these carries risk of failure or delay. Negative trial outcomes could reduce the future growth pipeline.

- Legal Challenges: Biofrontera has been embroiled in patent and trade-secret litigation with a competitor (DUSA Pharmaceuticals, a subsidiary of Sun Pharma) over PDT technology. Legal disputes have already imposed heavy costs – the company’s SG&A expenses rose in 2024–25 due in part to “increased legal expenses… driven by patent claim related costs” (www.biospace.com). Ongoing litigation not only diverts cash (legal fees) but could, in a worst-case scenario, result in damages or injunctions that affect Biofrontera’s business. Investors should keep an eye on the status of these legal cases; a resolution (or lack thereof) could materially impact the company’s financials.

- Affiliate/Control Risks: Following the asset purchase, Biofrontera’s former parent Biofrontera AG now holds a significant stake in the company via convertible preferred stock (Series D). While this gave the U.S. entity independence over Ameluz, it also means the German parent retains influence – the Series D shares carry voting rights on an as-converted basis (www.sec.gov) (capped at ~19.9% ownership to comply with Nasdaq rules). Biofrontera’s CEO, Dr. Hermann Lübbert, was also the founder and a major shareholder of Biofrontera AG. This overlap raises potential governance conflicts: decisions by management could favor the interests of the large insider shareholder (BFAG) at times. That said, the restructuring aligned both companies’ incentives around Ameluz’s U.S. success (BFAG benefits as a royalty recipient and shareholder), so outright conflicts may be limited. Nonetheless, investors should be aware of this intertwined relationship and monitor any related-party dealings.

Open Questions & Outlook

1. FDA Outcome for sBCC: Will the FDA approve Ameluz-PDT for superficial basal cell carcinoma by the PDUFA deadline in late 2026? Approval could open a significant new market and bolster Biofrontera’s growth, but a delay or rejection would be a major setback. The FDA’s review and any advisory committee commentary will be important to watch.

2. Path to Profitability: Can Biofrontera reach breakeven with its current cash on hand and revenue trajectory, or will it need to raise additional capital in 2026? Management has expressed optimism that the new royalty structure and growing sales could drive improved profitability (www.globenewswire.com). Investors will be looking for evidence in upcoming quarterly results that operating losses are narrowing. If cash burn continues at current rates, the timing and terms of any needed financing (or strategic partnership) remains an open question.

3. Market Adoption and Reimbursement: How quickly will dermatologists adopt Ameluz-PDT for new indications if approved (sBCC, acne, broader AK use)? Convincing practitioners to change treatment habits takes time. A key related question is how insurance companies will reimburse these PDT treatments. Will Medicare and private insurers readily cover Ameluz for superficial BCC at sufficient rates? Biofrontera may need to invest in market education and possibly expand its salesforce, which could impact near-term expenses.

4. Legal Resolution: When and how will the patent litigation with DUSA/Sun Pharma be resolved? An out-of-court settlement or win could remove a cloud over Biofrontera and reduce legal expenses. Conversely, an adverse outcome could impose financial penalties or operational restrictions. This legal overhang is an uncertainty that the company and investors are keen to see resolved.

5. Pipeline and Strategy: Beyond the current label expansion, what is Biofrontera’s strategy for its pipeline? The company is completing trials for Ameluz in treating acne vulgaris and AK on the body. How large are these opportunities, and will Biofrontera consider partnering (especially for acne, which is a large primary care market) or continue to go it alone in commercialization? Additionally, given the stock’s low valuation, will management explore strategic alternatives (such as mergers or deeper partnerships) to unlock shareholder value if the market continues to undervalue the company?

Conclusion: Biofrontera’s recent FDA filing for Ameluz in skin cancer is a promising catalyst that could boost the company’s prospects in the long run. The potential to treat basal cell carcinoma expands Ameluz’s addressable market and reinforces PDT’s role in dermatology. However, from an equity standpoint, Biofrontera remains a high-risk, high-reward story. The company has no dividends and a leveraged equity model, modest valuation metrics, and several uncertainties to navigate. Improvement in fundamentals – accelerating revenue growth, disciplined cost management, and successful regulatory outcomes – will be critical for Biofrontera to justify a higher stock price and to reduce its reliance on external financing. Investors should watch upcoming quarters for execution on sales growth (especially if new indications come online) and any signals that Biofrontera can turn the corner toward profitability without overly diluting current shareholders. The FDA’s decision on sBCC and the resolution of outstanding risks will likely determine whether PDT with Ameluz can fulfill its promise as a game-changer in skin cancer treatment – and, by extension, whether BFRI stock can deliver rewarding returns to patient shareholders.